Macopharma
Macopharma, a leading player in the medical device industry, is headquartered in France and operates extensively across Europe, Asia, and the Americas. Founded in 1984, the company has established itself as a pioneer in the development of innovative solutions for blood transfusion, cellular therapy, and bioprocessing. With a strong focus on quality and safety, Macopharma offers a range of unique products, including blood bags, apheresis systems, and cell therapy solutions, designed to enhance patient care and streamline medical procedures. The company is recognised for its commitment to research and development, achieving significant milestones that have solidified its market position. Macopharma's dedication to excellence and innovation has earned it a reputation as a trusted partner in the healthcare sector, making it a preferred choice for medical professionals worldwide.
DitchCarbon Score
How does Macopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Macopharma's score of 39 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Macopharma's reported carbon emissions
In 2023, Macopharma reported total carbon emissions of approximately 48,050,000 kg CO2e. This figure includes 2,040,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 5,050,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity. The majority of their emissions, about 40,960,000 kg CO2e, fall under Scope 3, which encompasses all other indirect emissions in the value chain. Comparatively, in 2022, Macopharma's total emissions were about 48,950,000 kg CO2e, with Scope 1 emissions at 3,010,000 kg CO2e, Scope 2 at 5,620,000 kg CO2e, and Scope 3 at 40,320,000 kg CO2e. In 2021, the total emissions were approximately 48,310,000 kg CO2e, with similar distributions across the scopes. Despite these figures, Macopharma has not set specific reduction targets or initiatives as part of their climate commitments, nor do they appear to be part of any recognised climate pledges or initiatives such as the Science Based Targets initiative (SBTi). The absence of documented reduction targets suggests a need for further commitment to climate action within the organisation. Overall, while Macopharma has made strides in tracking and reporting emissions, the lack of defined reduction strategies indicates an opportunity for enhanced climate leadership.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 3,010,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,620,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 39,680,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Macopharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
